From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers “has been breached"

With new personnel moves at Ovid Therapeutics, Bristol Myers Squibb, AstraZeneca, and more, here are the latest comings and goings in the pharma industry.

Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal

Novo Nordisk's diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world study of certain U.S. patients

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid. Shares of the drugmaker rose more than 2% to $47 in premarket trading. Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including Revlimid, rose 1% to $12.3 billion. Analysts, on average, were looking for revenue of $11.4 billion, according to LSEG data. The U.S. drugmaker said it earned $2.9 billion, or $1.46 per share, down from $4.2 billion, or $2.07, a year earlier. Analysts had expected earnings of $1.07 a share. "The majority of our brands outperformed consensus in the quarter," Chief Financial Officer David Elkins said in an interview. "We just have really solid commercial execution." Sales of Eliquis, which Bristol Myers (NYSE:BMY) shares with Pfizer (NYSE:PFE), rose 8% to $3.7 billion in the quarter, while cancer immunotherapy Opdivo brought in $2.6 billion, up 7% from a year ago. Analysts, on average, had forecast sales of $3.3 billion and $2.3 billion for those drugs, respectively. Revlimid sales fell 38% to $838 million, but still topped analyst estimates by about $300 million. Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but $5.8 billion last year due to generic rivals. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue. Still, Revlimid has held up better than initially feared, and the company now expects 2025 sales of around $3 billion, Chief Commercialization Officer Adam Lenkowsky said. The company had previously said it expected 2025 Revlimid sales to be near $2.5 billion. It now expects full-year earnings, including a charge from a development deal with Germany’s BioNTech (NASDAQ:BNTX), to be $6.35 to $6.65 a share. Analysts are estimating 2025 earnings of around $6.24 per share.

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs

(Reuters) -Bristol Myers and Pfizer (NYSE:PFE) said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices. The initiative - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment’s monthly cost from around $606 to $346. But it would still cost over 9 times the average out-of-pocket cost paid by commercially insured patients. It is also significantly higher than the $231 per month Medicare price that former President Joe Biden’s administration negotiated under the Inflation Reduction Act, which is set to take effect next year, and the price of the drug abroad. "This discount is not as meaningful as that delivered through the IRA negotiations - those discounts have been ridiculed by Trump as not meaningful, so there’s potential for skepticism from the administration on this offer," Bernstein analyst Courtney Breen said in a note. While more than 90% of Eliquis prescriptions in the U.S. are currently covered through insurance, the drugmakers say the initiative aims to expand access, reduce out-of-pocket burden, and provide transparent pricing and direct support. Meanwhile, the Trump administration has ramped up efforts to tackle high U.S. prescription drug prices through a "most-favored-nation" (MFN) policy, aiming to align domestic prices with the lowest levels paid by comparable high-income countries. According to a 2024 report from the Senate’s Health, Education, Labor and Pensions committee, the cost of Eliquis was around $55 a month in France and $65 a month in the UK and Germany. Since its launch, Eliquis has been prescribed to over 15 million Americans and in 2024 it generated about $11.4 billion in global revenue.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with

Report: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815 million in 2023.